LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 4, 2011, Pages

  Ishida, Hidekazu ^a   Kogaki, Shigetoyo ^a   Narita, Jun ^a   Ichimori, Hiroaki ^a   Nawa, Nobutoshi ^a   Okada, Yoko ^a   Takahashi, Kunihiko ^b   Ozono, Keiichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

Author keywords

Cardiomyocyte differentiation; Glycogen synthase kinase 3 ; Hypertrophic cardiomyopathy; LEOPARD syndrome; Src homology 2 containing protein phosphatase 2

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BETA CATENIN; GLUTAMIC ACID; GLUTAMINE; GLYCOGEN SYNTHASE KINASE 3BETA; GREEN FLUORESCENT PROTEIN; MUTANT PROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR TBX5;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL MATURATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DISEASE SEVERITY; EMBRYO; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; HYPERTROPHIC CARDIOMYOPATHY; LEOPARD SYNDROME; MOUSE; MUSCLE FIBRIL; NONHUMAN; NOONAN SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL EXPANSION; UPREGULATION; WILD TYPE;

ANIMALS; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CARDIOMEGALY; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLYCOGEN SYNTHASE KINASE 3; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LEOPARD SYNDROME; MICE; MUTATION; MYOCYTES, CARDIAC; MYOFIBRILS; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 80053279943     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00216.2011     Document Type: Article

References (32)

1. Carvajal Vergara X, Sevilla A, D'Souza SL, Ang YS, Schaniel C, Lee DF, Yang L, Kaplan AD, Adler ED, Rozov R, Ge Y, Cohen N, Edelmann LJ, Chang B, Waghray A, Su J, Pardo S, Lichtenbelt KD, Tartaglia M, Gelb BD, Lemischka IR. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465: 808-812, 2010.
2. Cohen ED, Wang Z, Lepore JJ, Lu MM, Taketo MM, Epstein DJ, Morrisey EE. Wnt/beta-catenin signaling promotes expansion of Isl-1- positive cardiac progenitor cells through regulation of FGF signaling. J Clin Invest 117: 1794-1804, 2007.
3. Cohen ED, Tian Y, Morrisey EE. Wnt signaling: an essential regulator of cardiovascular differentiation, morphogenesis and progenitor self-renewal. Development 135: 789-798, 2008.
4. Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, Marino B, Pizzuti A, Dallapiccola B. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 71: 389-394, 2002.
5. Digilio MC, Sarkozy A, Pacileo G, Limongelli G, Marino B, Dallapiccola B. PTPN11 gene mutations: linking the Gln510Glu mutation to the "LEOPARD syndrome phenotype". Eur J Pediatr 165: 803-805, 2006.
6. Edouard T, Montagner A, Dance M, Conte F, Yart A, Parfait B, Tauber M, Salles JP, Raynal P. How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms? Cell Mol Life Sci 64: 1585-1590, 2007.
7. Edouard T, Combier JP, Nedelec A, Bel Vialar S, Metrich M, Conte Auriol F, Lyonnet S, Parfait B, Tauber M, Salles JP, Lezoualc'h F, Yart A, Raynal P. Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3β signaling. Mol Cell Biol 30: 2498-2507, 2010.
8. Faienza MF, Giordani L, Ferraris M, Bona G, Cavallo L. PTPN11 gene mutation and severe neonatal hypertrophic cardiomyopathy: what is the link? Pediatr Cardiol 30: 1012-1015, 2009.
9. Feng GS. Shp2-mediated molecular signaling in control of embryonic stem cell self-renewal and differentiation. Cell Res 17: 37-41, 2007.
10. Gessert S, Kuhl M. The multiple phases and faces of wnt signaling during cardiac differentiation and development. Circ Res 107: 186-199, 2010.
11. Habara Ohkubo A. Differentiation of beating cardiac muscle cells from a derivative of P19 embryonal carcinoma cells. Cell Struct Funct 21: 101-110, 1996.
12. Hanna N, Montagner A, Lee WH, Miteva M, Vidal M, Vidaud M, Parfait B, Raynal P. Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. FEBS Lett 580: 2477-2482, 2006.
13. Haq S, Michael A, Andreucci M, Bhattacharya K, Dotto P, Walters B, Woodgett J, Kilter H, Force T. Stabilization of β-catenin by a Wntindependent mechanism regulates cardiomyocyte growth. Proc Natl Acad Sci USA 100: 4610-4615, 2003.
14. Jopling C, van Geemen D, den Hertog J. Shp2 knockdown and Noonan/ LEOPARD mutant Shp2-induced gastrulation defects. PLoS Genet 3: e225, 2007.
15. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 281: 6785-6792, 2006.
16. Kwon C, Arnold J, Hsiao EC, Taketo MM, Conklin BR, Srivastava D. Canonical Wnt signaling is a positive regulator of mammalian cardiac progenitors. Proc Natl Acad Sci USA 104: 10894-10899, 2007.
17. Langdon YG, Goetz SC, Berg AE, Swanik JT, Conlon FL. SHP-2 is required for the maintenance of cardiac progenitors. Development 134: 4119-4130, 2007.
18. Limongelli G, Pacileo G, Marino B, Digilio MC, Sarkozy A, Elliott P, Versacci P, Calabro P, De Zorzi A, Di Salvo G, Syrris P, Patton M, McKenna WJ, Dallapiccola B, Calabro R. Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. Am J Cardiol 100: 736-741, 2007.
19. Limongelli G, Sarkozy A, Pacileo G, Calabro P, Digilio MC, Maddaloni V, Gagliardi G, Di Salvo G, Iacomino M, Marino B, Dallapiccola B, Calabro R. Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome. Am J Med Genet A 146A: 620-628, 2008.
20. Naito AT, Akazawa H, Takano H, Minamino T, Nagai T, Aburatani H, Komuro I. Phosphatidylinositol 3-kinase-Akt pathway plays a critical role in early cardiomyogenesis by regulating canonical Wnt signaling. Circ Res 97: 144-151, 2005.
21. Naito AT, Shiojima I, Akazawa H, Hidaka K, Morisaki T, Kikuchi A, Komuro I. Developmental stage-specific biphasic roles of Wnt/β-catenin signaling in cardiomyogenesis and hematopoiesis. Proc Natl Acad Sci USA 103: 19812-19817, 2006.
22. Nakamura T, Sano M, Songyang Z, Schneider MD. A Wnt- and β-catenin-dependent pathway for mammalian cardiac myogenesis. Proc Natl Acad Sci USA 100: 5834-5839, 2003.
23. Qu CK, Feng GS. Shp-2 has a positive regulatory role in ES cell differentiation and proliferation. Oncogene 17: 433-439, 1998.
24. Shi ZQ, Yu DH, Park M, Marshall M, Feng GS. Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity. Mol Cell Biol 20: 1526-1536, 2000.
25. Sobreira NL, Cirulli ET, Avramopoulos D, Wohler E, Oswald GL, Stevens EL, Ge D, Shianna KV, Smith JP, Maia JM, Gumbs CE, Pevsner J, Thomas G, Valle D, Hoover Fong JE, Goldstein DB. Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene. PLoS Genet 6: e1000991, 2010.
26. Takahashi K, Kogaki S, Kurotobi S, Nasuno S, Ohta M, Okabe H, Wada K, Sakai N, Taniike M, Ozono K. A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy. Eur J Pediatr 164: 497-500, 2005.
27. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29: 465-468, 2001.
28. Tidyman WE, Rauen KA. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Expert Rev Mol Med 10: e37, 2008.
29. Tseng AS, Engel FB, Keating MT. The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes. Chem Biol 13: 957-963, 2006.
30. Ueno S, Weidinger G, Osugi T, Kohn AD, Golob JL, Pabon L, Reinecke H, Moon RT, Murry CE. Biphasic role for Wnt/β-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. Proc Natl Acad Sci USA 104: 9685-9690, 2007.
31. Wu D, Pang Y, Ke Y, Yu J, He Z, Tautz L, Mustelin T, Ding S, Huang Z, Feng GS. A conserved mechanism for control of human and mouse embryonic stem cell pluripotency and differentiation by shp2 tyrosine phosphatase. PLoS One 4: e4914, 2009.
32. Xu D, Wang S, Yu WM, Chan G, Araki T, Bunting KD, Neel BG, Qu CK. A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells. Blood 116: 3611-3621, 2010.